| P50 | author | Francisco Marín | Q85342817 |
| | Mariano Valdés Chávarri | Q102078444 |
| | Diana Hernández-Romero | Q114561142 |
| | Vanessa Roldan | Q56754352 |
| | Gregory Lip | Q60393087 |
| P2093 | author name string | Francisco Cambronero | |
| P2860 | cites work | Altered regulatory properties of human cardiac troponin I mutants that cause hypertrophic cardiomyopathy | Q22254076 |
| | Mutations in the gamma(2) subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: evidence for the central role of energy compromise in disease pathogenesis | Q24291256 |
| | Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule | Q24305174 |
| | Identification of a gene responsible for familial Wolff-Parkinson-White syndrome | Q28201949 |
| | Familial hypertrophic cardiomyopathy: from mutations to functional defects | Q28282839 |
| | Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy | Q28344111 |
| | Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy | Q28348531 |
| | Altered crossbridge kinetics in the alphaMHC403/+ mouse model of familial hypertrophic cardiomyopathy | Q28506679 |
| | In vivo modeling of myosin binding protein C familial hypertrophic cardiomyopathy | Q28512273 |
| | Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy | Q28570951 |
| | Cardiac hypertrophy: the good, the bad, and the ugly | Q29615247 |
| | Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor alpha can be modulated by anti-tumor necrosis factor alpha therapy | Q30479528 |
| | Prognosis and mortality of hypertrophic obstructive cardiomyopathy | Q33170393 |
| | Cerebrovascular complications associated with idiopathic hypertrophic subaortic stenosis | Q33172587 |
| | Insulin-like growth factor I as a cardiac hormone: physiological and pathophysiological implications in heart disease | Q33790540 |
| | Quantitative analysis of myocardial fibrosis in normals, hypertensive hearts, and hypertrophic cardiomyopathy | Q34048715 |
| | Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults | Q34058337 |
| | Decoding calcium signals involved in cardiac growth and function | Q34076156 |
| | Hypertrophic cardiomyopathy: a systematic review | Q34117625 |
| | Sudden death in young athletes | Q34229613 |
| | Continuous activation of gp130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice | Q34270015 |
| | Contraction-induced myokine production and release: is skeletal muscle an endocrine organ? | Q34432712 |
| | Cardiac fibrosis as a cause of diastolic dysfunction | Q34651778 |
| | Hypertrophic cardiomyopathy:a paradigm for myocardial energy depletion | Q35113389 |
| | Hypertrophic cardiomyopathy: the interrelation of disarray, fibrosis, and small vessel disease | Q35376769 |
| | Deficit of in vivo mitochondrial ATP production in patients with Friedreich ataxia | Q35653693 |
| | Hypertrophy of the heart: a new therapeutic target? | Q35739349 |
| | Pathways of matrix metalloproteinase induction in heart failure: bioactive molecules and transcriptional regulation | Q36373665 |
| | Genes, calcium and modifying factors in hypertrophic cardiomyopathy | Q36381489 |
| | Inflammatory biomarkers in acute coronary syndromes: part II: acute-phase reactants and biomarkers of endothelial cell activation | Q36402102 |
| | Inflammatory biomarkers in acute coronary syndromes: part III: biomarkers of oxidative stress and angiogenic growth factors | Q36408208 |
| | Inflammatory biomarkers in acute coronary syndromes: part IV: matrix metalloproteinases and biomarkers of platelet activation | Q36415152 |
| | A contemporary approach to hypertrophic cardiomyopathy. | Q36511747 |
| | Coronary microvascular dysfunction | Q36741793 |
| | Antifibrotic effects of antioxidant N-acetylcysteine in a mouse model of human hypertrophic cardiomyopathy mutation | Q37410985 |
| | Alteration of cardiac and renal functions in transgenic mice overexpressing human mineralocorticoid receptor | Q38297956 |
| | Matrix metalloproteinases and cardiovascular disease | Q40410789 |
| | Basic mechanisms in congestive heart failure. Recognizing the role of proinflammatory cytokines | Q40726747 |
| | Cytokine production and antibodies against heat shock protein 60 in cardiomyopathies of different origins | Q40827801 |
| | von Willebrand factor: a marker of endothelial dysfunction in vascular disorders? | Q41517185 |
| | Measurements of cardiac troponin T in patients with hypertrophic cardiomyopathy | Q42995490 |
| | Difference in coronary blood flow dynamics between patients with hypertension and those with hypertrophic cardiomyopathy | Q44229510 |
| | Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy | Q44454565 |
| | Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure | Q44468973 |
| | Myocardial collagen turnover in hypertrophic cardiomyopathy | Q44571604 |
| | Plasma levels of atrial natriuretic peptide in hypertrophic cardiomyopathy | Q44991825 |
| | Plasma monitoring of the myocardial specific tissue inhibitor of metalloproteinase-4 after alcohol septal ablation in hypertrophic obstructive cardiomyopathy. | Q45283113 |
| | Effect of Losartan on left ventricular diastolic function in patients with nonobstructive hypertrophic cardiomyopathy | Q46822465 |
| | Comparison of circulating levels of interleukin-6 and tumor necrosis factor-alpha in hypertrophic cardiomyopathy and in idiopathic dilated cardiomyopathy | Q47216767 |
| | Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha | Q47625962 |
| | Increased circulating matrix metalloproteinase-2 in patients with hypertrophic cardiomyopathy with systolic dysfunction | Q47842313 |
| | Screening for familial hypertrophic cardiomyopathy using brain natriuretic peptide | Q48189434 |
| | Increased plasma levels of brain natriuretic peptide in hypertrophic cardiomyopathy | Q48234276 |
| | Ventricular expression of brain natriuretic peptide in hypertrophic cardiomyopathy | Q48239403 |
| | Plasma brain natriuretic peptide as an indicator for angiotensin-converting-enzyme inhibition after myocardial infarction | Q48298813 |
| | Usefulness of N-terminal pro-B-type natriuretic peptide to predict clinical course in patients with hypertrophic cardiomyopathy | Q48358107 |
| | Usefulness of N-terminal pro-B-type natriuretic peptide levels to predict exercise capacity in hypertrophic cardiomyopathy | Q48452828 |
| | Marked expression of plasma brain natriuretic peptide is a special feature of hypertrophic obstructive cardiomyopathy | Q48883465 |
| | Analysis of circulating apoptosis mediators and proinflammatory cytokines in patients with idiopathic hypertrophic cardiomyopathy: comparison between nonobstructive and dilated-phase hypertrophic cardiomyopathy | Q48898672 |
| | Usefulness of B-type natriuretic peptide assay in the assessment of symptomatic state in hypertrophic cardiomyopathy. | Q51033464 |
| | Alterations of the architecture of subendocardial arterioles in patients with hypertrophic cardiomyopathy and impaired coronary vasodilator reserve: a possible cause for myocardial ischemia. | Q53785646 |
| | Myocardial ultrastructure in idiopathic hypertrophic subaortic stenosis. A study of operatively excised left ventricular outflow tract muscle in 14 patients. | Q54486630 |
| | Determinants of coronary microvascular dysfunction in symptomatic hypertrophic cardiomyopathy | Q57607649 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | biomarker | Q864574 |
| | pathophysiology | Q1135939 |
| | hypertrophic cardiomyopathy | Q1364270 |
| P304 | page(s) | 139-151 | |
| P577 | publication date | 2009-01-09 | |
| P1433 | published in | European Heart Journal | Q2286839 |
| P1476 | title | Biomarkers of pathophysiology in hypertrophic cardiomyopathy: implications for clinical management and prognosis | |
| P478 | volume | 30 | |